sgp130 in Chronic Human Liver Disease

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT00770198
First received: October 8, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.


Condition
Alcoholic Liver Disease
Chronic Hepatitis C Virus Infection

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of IL-6 Transsignaling in Chronic Human Liver Disease

Resource links provided by NLM:


Further study details as provided by Erasme University Hospital:

Biospecimen Retention:   Samples Without DNA

plasma, liver biopsies, and peripheral blood mononuclear cell culture medium.


Enrollment: 129
Study Start Date: January 2005
Study Completion Date: October 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
alcoholic liver disease
alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
chronic HCV hepatitis
chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution

Detailed Description:

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients of Erasme University Hospital

Criteria

Inclusion Criteria:

  • Alcohol excess intake and suspected liver disease
  • Alcohol excess intake and clinical liver cirrhosis
  • chronic hepatitis C virus infection and suspected liver disease
  • chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria:

  • other (superimposed) liver disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00770198

Locations
Belgium
Hopital Erasme - Dpt of Gastroenterology
Brussels, Belgium, 1070
Sponsors and Collaborators
Erasme University Hospital
Investigators
Principal Investigator: Arnaud Lemmers, MD Erasme Hospital, Gastroenterology Dpt
  More Information

No publications provided

Responsible Party: Olivier Le Moine, MD, PhD, Erasme University Hospital
ClinicalTrials.gov Identifier: NCT00770198     History of Changes
Other Study ID Numbers: AL-gp130
Study First Received: October 8, 2008
Last Updated: October 8, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by Erasme University Hospital:
liver
alcohol
HCV

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Liver Diseases
Liver Diseases, Alcoholic
Virus Diseases
Hepatitis C, Chronic
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on April 16, 2014